XERS
Xeris Pharmaceuticals Inc
10.20$
+0.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -423.0% | – | – | – | -607.9% | – | +10,027.5% | +8.7% | -50.8% | -16.3% | – | |
| – | -2.9% | -1.4% | -1.9% | -15.1% | +17.0% | +0.3% | +0.7% | +0.8% | -4.5% | +5.4% | +0.0% | – | |
| – | +12.6% | +36.1% | +12.4% | +59.9% | -46.9% | +23.6% | +12.7% | +52.6% | -31.0% | -21.5% | +167.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -131.6% | – | – | -105.3% | – | – | – | -106.1% | – | – | – | |
| – | -61.7% | +24.2% | +142.1% | -78.1% | +152.9% | -94.1% | +2,046.2% | +30.1% | -8.3% | -2.4% | -35.7% | – | |
| – | +1.5% | -232.2% | – | +115.4% | +1.0% | -100.1% | +2,046.2% | -74.6% | +369.0% | -2.4% | -35.7% | – | |
| – | -31.9% | +6,908.2% | -98.5% | +62.7% | +100.0% | +4,718.1% | -89.2% | -44.4% | +222.2% | +1,005.0% | -98.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -31.9% | – | -98.1% | -112.6% | – | -888.2% | – | +1,370.3% | -101.9% | +3,222.2% | – | – | |
| – | – | -122.3% | – | – | +711.9% | -206.4% | – | +3,712.0% | -39.6% | -96.4% | +1,312.0% | – | |
| – | – | -432.6% | – | – | – | -672.3% | – | – | +9.1% | -51.6% | -15.6% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.